WASHINGTON—Because widely used anemia drugs may double the risk of stroke in patients with kidney disease, the Food and Drug Administration is considering new restrictions on them. On Thursday, the FDA posted a safety review of three medications from Amgen Inc., Epogen, Procrit, and Aranesp.
To read an Associated Press article on this topic, click HERE.
Â
